Recently, joint research by Shenzhen Dieckmann Biotechnology Co., Ltd. and Guangdong Pharmaceutical University, Synthesis of a Novel C46‑Ceramide and Its Skin Barrier Repairing Efficacy Validated via Molecular Dynamics and Cellular Assays, has been formally published in Journal of Holistic Integrative Pharmacy.

This research systematically elaborates the green synthetic route, molecular mechanism and skin‑barrier‑repairing performance of the innovative ultra‑long‑chain. At the molecular level, it demonstrates its significant advantages over conventional shorter‑chain Ceramide 3B. This marks another key academic achievement from Dieckmann following its continuous innovation in the ceramide field.

Original Innovation: Golden C46‑Ceramide EOP

Ceramides are core components of the skin barrier, and ultra‑long‑chain ceramides are critical for forming compact lipid lamellar structures. Within human skin, the C46 carbon‑chain ceramide represents the most abundant ceramide subclass.

Guided by biomimetic design principles, Dieckmann’s R&D team has successfully synthesized the novel ultra‑long‑chain Golden C46‑Ceramide EOP, which is protected by a compound patent (Patent No.: ZL 2022 1 1238109.X). This breakthrough breaks international monopolies and fills the domestic gap for Ceramide EOP. Research Highlights: Targeted Skin Barrier Repair Published findings systematically verify the barrier‑repairing capacity of Golden C46‑Ceramide EOP from molecular mechanisms to cellular levels. Through multi‑target synergistic effects, it builds a healthy skin ecosystem across three dimensions: inflammation modulation (IL‑6), skin hydration (AQP3), and elastic‑structure protection (ELANE). It exhibits superior performance compared with conventional shorter‑chain Ceramide 3B, providing rigorous academic validation for Golden C46‑Ceramide EOP. The study also presents an AI‑empowered workflow for precise ceramide R&D and biological validation: from network pharmacology data mining and analysis, to AI‑driven simulation and computation, and experimental support with automated screening. It offers new insights for AI‑assisted development of high‑performance cosmetic active ingredients. With rising market and clinical attention to sensitive‑skin care and skin‑health ecosystems, developing a novel Ceramide EOP with well‑defined structure, clarified mechanism and high safety profile addresses both academic pursuits and urgent market demands. Dieckmann Biotechnology: Redefining Ceramides Developed to solve unmet market needs, Dieckmann’s Golden C46‑Ceramide EOP is a mature active ingredient validated by solid academic evidence and real‑world market performance. Since its launch, this active raw material has won multiple authoritative industry awards and has been adopted in commercial products from numerous well‑known domestic and international beauty brands. Dieckmann Biotechnology is committed to redefining the global positioning of ceramides within the cosmetics industry, spearheading a new era of skin‑barrier repair with original scientific‑research capabilities. Currently, Dieckmann has built a full‑chain solution covering molecular design, green synthesis, efficacy validation and application support, positioning the company as a leading domestic provider of integrated ceramide solutions. Moving forward, Dieckmann will keep deepening its R&D on ceramide, polypeptide and vitamin‑A‑series active ingredients. The company aims to infuse “Chinese‑originated innovations” into every active raw material and empower beauty brands worldwide.